APO-CLOBAZAM 10 MG — DIN 02244638
CLOBAZAM : 10 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-CLOBAZAM?
APO-CLOBAZAM 10 MG contains CLOBAZAM : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02244638, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Nov-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CLOBAZAM used for?
Adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anticonvulsant therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Clobazam cost around the world?
Clobazam is listed on 16 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 23 | USD███.██ |
| South Africa | single exit price | 9 | 11 | ZAR███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Bahrain | retail (max) | 1 | 4 | BHD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 2 | 4 | BRL███.██ |
| Spain | PVP con IVA (public price) | 4 | 4 | EUR███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| Saudi Arabia | public | 1 | 2 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
69 pack listings across 39 brand entries and 14 price bases, refreshed 05 Sep 2026. Ranges span every Clobazam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Clobazam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Clobazam, across 10 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 1 | NTP-CLOBAZAM, TEVA-CLOBAZAM | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-CLOBAZAM | Sourceable in Canada |
| DOMINION PHARMACAL | 1 | 0 | DOM-CLOBAZAM | No marketed DIN |
| HOECHST CANADA INC. | 1 | 0 | FRISIUM TAB 10MG | No marketed DIN |
| HOECHST ROUSSEL CANADA INC. | 1 | 0 | FRISIUM TABLETS 10MG | No marketed DIN |
| LUNDBECK PHARMACEUTICALS LLC | 1 | 0 | FRISIUM TABLET 10MG | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-CLOBAZAM | No marketed DIN |
| PRO DOC LIMITEE | 1 | 0 | CLOBAZAM-10 | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 1 | 0 | RATIO-CLOBAZAM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (mentions "Dosage Forms, Composition and Packaging" section but specific bottle sizes are not listed in the snippet). |
| Storage | Not explicitly detailed in the provided text (section header exists but content is missing from snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Clobazam |
|---|---|
| ATC code | N05BA09 |
| AHFS class | 28:36.20.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02244638 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2244638 |
| Brand name | APO-CLOBAZAM |
| Generic / active ingredient | CLOBAZAM : 10 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA09 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BA |
| Current status | MARKETED |
| Status date | 28-Nov-2001 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adjunctive therapy in epilepsy. Start with low doses, especially in elderly/renal/hepatic patients. Avoid abrupt discontinuation; terminate by gradually tapering the dosage.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; myasthenia gravis; narrow angle glaucoma; history of drug/alcohol dependence; severe respiratory insufficiency; sleep apnoea; severe liver impairment; 1st trimester of pregnancy.
Warnings and precautions
Risk of addiction, abuse, misuse; life-threatening withdrawal; risks from concomitant use with opioids; serious skin reactions (SJS, TEN, DRESS); suicidal ideation; respiratory depression.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-CLOBAZAM | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02238334 |
| CLOBAZAM-10 | 10 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 02248454 |
| DOM-CLOBAZAM | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02247230 |
| FRISIUM TAB 10MG | 10 MG | TABLET | HOECHST CANADA INC. | CANCELLED POST MARKET | 00846392 |
| FRISIUM TABLET 10MG | 10 MG | TABLET | LUNDBECK PHARMACEUTICALS LLC | CANCELLED POST MARKET | 02221799 |
| FRISIUM TABLETS 10MG | 10 MG | TABLET | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | 01989634 |
| NTP-CLOBAZAM | 10 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | 02347598 |
| PMS-CLOBAZAM | 10 MG | TABLET | PHARMASCIENCE INC | DORMANT | 02244474 |
| RATIO-CLOBAZAM | 10 MG | TABLET | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | 02238797 |
2 · Same class — other molecules in ATC N05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lorazepam | APO-LORAZEPAM · ATIVAN · ATIVAN INJ 4MG/ML · ATIVAN INJECTION LIQ 4MG/ML · +21 more | 53 | 17 | Yes |
| Alprazolam | ALPRAZOLAM · ALPRAZOLAM TABLETS 0.25 · ALPRAZOLAM TABLETS 0.5MG · APO-ALPRAZ · +17 more | 50 | 13 | Yes |
| Oxazepam | APO-OXAZEPAM · BIO-OXAZEPAM · NOVOXAPAM TAB 10MG · NOVOXAPAM TAB 15MG · +17 more | 31 | 9 | Yes |
| Diazepam | BIO-DIAZEPAM · DIASTAT · DIAZEMULS · DIAZEPAM · +23 more | 38 | 8 | Yes |
| Bromazepam | ALTI-BROMAZEPAM 1.5MG TABLETS · ALTI-BROMAZEPAM 3MG TABLETS · ALTI-BROMAZEPAM 6MG TABLETS · APO-BROMAZEPAM · +14 more | 24 | 4 | Yes |
| Clorazepate Potassium | CLORAZEPATE · NOVO-CLOPATE CAP 15MG · NOVO-CLOPATE CAP 3.75MG · NOVO-CLOPATE CAP 7.5MG · +3 more | 9 | 3 | Yes |
| Clobazam | APO-CLOBAZAM · CLOBAZAM-10 · DOM-CLOBAZAM · FRISIUM TAB 10MG · +6 more | 10 | 2 | Yes |
| Chlordiazepoxide | CHLORDIAZEPOXIDE · CHLORDIAZEPOXIDE CAP 10MG · CHLORDIAZEPOXIDE CAP 5MG · CHLORDIAZEPOXYDE 25 CAP · +10 more | 16 | 1 | Yes |
| Ketazolam | LOFTRAN CAP 30MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BE | Buspirone | 25 | 7 |
| N05BB | Hydroxyzine | 29 | 5 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-CLOBAZAM called?
The same molecule, Clobazam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FRISIUM | Latin | Brazil, Czechia |
| ZACCO | Latin | Bahrain |
| Urbanyl | Latin | Iceland, Morocco |
| Clogaba | Latin | Saudi Arabia |
| URBANIL | Latin | Brazil |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.